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Abstract
Hidradenitis suppurativa is a chronic, recurrent follicular
occlusion disease with painful, sometimes debilitating,
cutaneous draining lesions and subcutaneous abscesses
(DynaMed Plus, 2016). Hidradenitis suppurativa is
understood to be a multifactorial disease that is hard to treat
in some patients, especially those with a severe form of the
disease. For this project, the efficacy of adalimumab for
hidradenitis suppurativa was assessed and whether it is
more beneficial than traditional treatments used.
Adalimumab is a TNF-alpha inhibitor which belongs to the
biologic DMARDs drug class. Kimball et al. (2012) found
that at week 16 of their trial 3.9% of the placebo patients,
9.6% of every other week (EOW) dosing of adalimumab
patients, and 17.6% of every week dosing of adalimumab
patients achieved clinical response. Patient response
reports on pain and outcomes were significantly greater in
the weekly dosed patients vs. placebo group. A study by
Miller et al. (2011) showed a significant reduction in
Sartorious score after 6 weeks and an almost significant
reduction seen after 12 weeks when compared to the
placebo group (-10.7 vs. 7.5, P=0.024 and -11.3 vs. 5.8,
P=0.07). Kimball et al. (2016) showed clinical response
rates at week 12 were significantly higher for the groups
receiving adalimumab weekly than for the placebo groups:
41.8% versus 26.0% in PIONEER I (P=0.003) and 58.9%
versus 27.6% in PIONEER II (P<0.001). DynaMed Plus,
PubMed, and Cochran Library were searched with key
words: hidradenitis suppurativa, adalimumab, and treatment.

Introduction
The etiology of hidradenitis suppurativa is not completely
understood but it is likely multifactorial with some of the
possible contributing factors including: genetics, hormones,
and aberrant immune response that causes upregulated
cytokines (DynaMed Plus, 2016). Risk factors include family
history, smoking, obesity, mechanical friction, and certain
medications (DynaMed Plus, 2016). Traditional treatments
for this disorder consisted of antibiotics, hormone therapy,
retinoids, corticosteroid injections, surgical intervention, pain
management, and patient counselling on weight loss and
smoking cessation. More recently, the tumor necrosis factoralpha (TNF-alpha) inhibitor adalimumab was approved by
the Food and Drug Administration (FDA) for treating
hidradenitis suppurativa

Statement of the Problem
There is no cure for hidradenitis suppurativa and although
there are many treatment options available, the traditional
treatments do not provide adequate relief of symptoms for
some patients. Adalimumab, though not a cure, may provide
more beneficial treatment then these traditional options
alone. This review was needed to evaluate research
supporting the efficacy of adalimumab for hidradenitis
suppurativa and to compare the risks and benefits of using
this medication.

Image taken from Lee et al. (2017)

Literature Review
• Kimbal et al. (2012) found that at week 16, 3.9% of the
placebo patients (2 of 51), 9.6% of the EOW patients (5 of
52) and 17.6% of weekly patients (9 of 51) achieved
clinical response
• Kimbal et al. (2012) also found that serious adverse
effects rates were 3.9% for placebo, 5.8% for EOW, and
7.8% for the weekly patients
• “In period I of each study there were significantly more
patients in the adalimumab group than the placebo group
that met the primary efficacy end point of clinical response
at week 12 (PIONEER I: 41.8% vs. 26.0%, P=0.003;
PIONEER II: 58.9% vs. 27.6%, P<0.001)” (Kimball, 2016)
• Miller et al. (2011) found a significant reduction of the
Sartorius score after 6 weeks and an almost significant
reduction after 12 weeks of active treatment when
compared to the placebo group (-10.7 vs. 7.5, P=0.024
and -11.3 vs. 5.8, P=0.07)
• Miller et al. (2011) state in their study that although
adalimumab was well tolerated, there were more adverse
effects seen in the adalimumab group than the placebo
group with regard to mild infections. “However, the
difference was only almost significant (P=0.16 and
P=0.79, respectively)” (Miller, 2011, p.395). All other
adverse effects were not significant in the adalimumab
group when compared to the placebo group

Research Question
• In patients with hidradenitis suppurativa is adalimumab
more effective than traditional treatments to include
antibiotics, hormone therapy, retinoids, corticosteroid
injections, surgical intervention, and pain management in
treatment outcomes?
• In patients with hidradenitis suppurativa does adalimumab
show better treatment outcomes in patients with severe
disease vs mild or moderate disease?
• In patients with hidradenitis suppurativa are the side effect
outcomes associated with adalimumab treatment more
significant or detrimental than side effect outcomes
associated with the traditional treatment options?

Discussion
• The studies used support the use of adalimumab for
hidradenitis suppurativa
• There were no placebo controlled trials found within the
last ten years to support the use of any of the traditional
treatment options for hidradenitis suppurativa
• Serious adverse effects rates were higher in patient groups
that were assigned adalimumab vs the placebo
• There is no data comparing adalimumab serious adverse
effects vs the serious adverse effects of any of the
traditional treatments used
• Adalimumab has only been assessed for moderate-tosevere hidradenitis suppurativa, therefore the efficacy for
adalimumab for mild hidradenitis suppurativa is unknown

Applicability to Clinical Practice
The current guidelines found on DynaMed Plus do
recommend adalimumab for moderate-to-severe
hidradenitis suppurativa, which is supported by my
research. These guidelines from DynaMed are very
applicable to clinic use, but there is no cure and treatment
is patient dependent with much trial and error. Hidradenitis
suppurativa is difficult to treat and should not be treated in
a primary care setting, this should be maintained by the
dermatology department. There are several different
scoring systems used to assess hidradenitis suppurativa
and dermatologists are better suited to track these scores
to assess how treatment is going. Some lifestyle
modifications such as smoking cessation, good control of
blood sugars with diabetic patients, and weight loss can
be encouraged in a primary care setting.
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